Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMIT-2 Trial for treatments of Crimean-Congo haemorrhagic fever
ISRCTN12205320Phase 2Recruiting
- Sponsor
- Liverpool School of Tropical Medicine
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial in Crimean–Congo hemorrhagic fever (CCHF) comparing Optimised Standard of Care, Favipiravir and Ribavirin (3 arms). Primary endpoint: Proportion of patients with undetectable CCHF viral RNA in blood by day 7. Started Jun 2026; status: recruiting.
02
Drugs
favipiravirribavirin
03
Conditions
Crimean–Congo hemorrhagic fever (CCHF)
Beyond the preview
Go deeper on ISRCTN12205320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12205320.